PRINCE PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.95 TWD | -0.18% |
|
-4.61% | -20.14% |
| Sales 2022 | 713M 21.99M 30.22M | Sales 2023 | 753M 23.25M 31.95M | Capitalization | 1.27B 39.1M 53.73M |
|---|---|---|---|---|---|
| Net income 2022 | 51M 1.57M 2.16M | Net income 2023 | 15M 463K 636K | EV / Sales 2022 * | - |
| Net Debt 2022 | 451M 13.92M 19.14M | Net Debt 2023 | 368M 11.35M 15.6M | EV / Sales 2023 | 2.17 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
83.3
x | Employees | 210 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.14% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.18% | ||
| 1 week | -4.61% | ||
| Current month | -4.61% | ||
| 1 month | +0.54% | ||
| 3 months | -16.82% | ||
| 6 months | -20.82% | ||
| Current year | -20.14% |
1 week
26.30
28.60
1 month
26.3031.00
Current year
26.3036.55
1 year
26.3044.75
3 years
26.3075.20
5 years
26.3075.20
10 years
26.3075.20
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Ta Li
CEO | Chief Executive Officer | - | - |
Tsui Wei Chen
DFI | Director of Finance/CFO | - | 08-06-01 |
Wan Hsiung Su
CTO | Chief Tech/Sci/R&D Officer | - | 91-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Yao Cheng
BRD | Director/Board Member | - | 23-01-17 |
Ying-Lin Huang
BRD | Director/Board Member | - | 23-01-17 |
Chi Ta Li
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 27.95 | -0.18% | 19,296 |
| 24-06-06 | 28 | +0.36% | 60 |
| 24-06-05 | 27.9 | -0.53% | 15,035 |
| 24-06-04 | 28.05 | +0.18% | 11,110 |
| 24-06-03 | 28 | -4.44% | 12,678 |
End-of-day quote Taipei Exchange, June 06, 2024
More quotes
Prince Pharmaceutical Co Ltd is a Taiwan-based Company engaged in the manufacture and sale of health food and ingredients. The Company's main business is divided into ingredients business and health food business. The ingredients business currently consists of phlegm dispelling agents, vitamin B1 derivatives, and non-steroidal anti-inflammatory drugs. The health food business is mainly engaged in the original equipment manufacturer (OEM) and original design manufacturer (ODM) of health food products, providing a series of integrated services from product formulation design, research and development to the production and packaging of various dosage forms. The Company sells its products mainly in domestic and overseas markets, including Japan and Korea.
Sector
Food Processing
| 1st Jan change | Capi. | |
|---|---|---|
| -20.14% | 31.18M | |
| +10.73% | 7.96B | |
| +8.44% | 7.66B | |
| -0.58% | 5.88B | |
| -6.11% | 3.72B | |
| -13.21% | 3.47B | |
| -15.49% | 1.16B | |
| +9.98% | 948M | |
| -11.42% | 905M | |
| -13.08% | 831M |
- Stock Market
- Equities
- 6935 Stock
